In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing
- 1 September 2007
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 51 (9) , 3378-3380
- https://doi.org/10.1128/aac.00496-07
Abstract
The posaconazole MIC 90 for 1,903 yeast isolates from France was 1 μg/ml (range, ≤0.015 to 8 μg/ml). Ninety percent of isolates with fluconazole MICs of ≥8 μg/ml ( n = 509) and 90% of those with voriconazole MICs of ≥2 μg/ml ( n = 80) were inhibited by 2 and 8 μg/ml of posaconazole, respectively.Keywords
This publication has 14 references indexed in Scilit:
- Clinical Significance of Azole Antifungal Drug Cross-Resistance in Candida glabrataJournal of Clinical Microbiology, 2006
- Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous FungiAntimicrobial Agents and Chemotherapy, 2006
- In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002–2003Journal of Antimicrobial Chemotherapy, 2005
- Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002Journal of Clinical Microbiology, 2004
- In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance programDiagnostic Microbiology and Infectious Disease, 2004
- Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United StatesAntimicrobial Agents and Chemotherapy, 2003
- In Vitro Activities of Voriconazole, Posaconazole, and Four Licensed Systemic Antifungal Agents against Candida Species Infrequently Isolated from BloodJournal of Clinical Microbiology, 2003
- In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida sppAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and VoriconazoleAntimicrobial Agents and Chemotherapy, 1998